Development of the <u>Hygiene Extension Limb position Pain (HELP)</u> Tool to monitor waning of clinical efficacy in patients with spasticity or cervical dystonia treated with botulinum toxins

Atul Patel, 1 Stefan Wietek, 2 Edward Dabrowski 3

¹Kansas City Bone and Joint Clinic, Overland Park, KS, United States; ²Ipsen, Cambridge, MA, United States; ³Oakland University School of Medicine and Beaumont Hospital, Grosse Pointe, MI, United States

BACKGROUND

- Spasticity, a stretch reflex disorder that manifests as a velocity-dependent increase in muscle tone, is commonly caused by upper motor neuron damage.1
- Cervical dystonia (CD) is a chronic neurological movement disorder characterized by excessive involuntary muscle contractions leading to abnormal head movements and neck pain.2
- Intramuscular injections of botulinum neurotoxin into the affected muscles is an approved first-line treatment for upper and lower limb spasticity³ and CD symptoms.⁴
- The waning of treatment effect over time is common and is estimated to impact 80% patients regularly treated with botulinum neurotoxin A (BoNT-A).⁵
- The development of the HELP Tool, a patient-reported outcome (PRO) instrument, is needed in order to provide greater discernment of waning clinical efficacy after BoNT-A injections prior to the next scheduled treatment.
- The HELP Tool is under development for utilization by adult or pediatric patients with upper and/or lower limb spasticity, adults with cervical dystonia (CD), and parents and caregivers.
- The impact of spasticity or CD symptom recurrence on patients will be more easily gauged with the HELP Tool, which will aid in determining appropriate treatment optimization.

OBJECTIVE

- The objective of this study is to present the progress of the development of HELP Tool, a PRO instrument. The key design goals for the HELP Tool include:
- Reportable by either patient or caregiver
- Takes 5-10 minutes to complete
- Self-administered
- Easy to score
- Usable in various settings (office/home) and media (paper/electronic)



METHODS

- Working with a consultant experienced in the development and psychometric validation of PRO instruments, a panel of 9 subject-matter experts developed preliminary ~20-item questionnaires for potential use with patients with spasticity and CD and their parents/caregivers.
- Content validity will be assessed qualitatively (via patient feedback) and the questionnaire will be modified to provide a clinically useful screening tool to identify when treatment is waning prior to the next scheduled BoNT-A treatment.
- Psychometric properties of the new tool will be assessed quantitatively.
- Patient satisfaction with treatment relevant to symptoms will also be evaluated.
- After the first 11 interviews of adult spasticity and CD patients for concept elicitation (CE), a virtual advisory board with subject matter experts was conducted to develop and refine a relevant and meaningful HELP Tool and ensure content validity.
- A second round of testing the questionnaires via interviews in a larger patient and parent/ caregiver cohort is underway, with subsequent HELP Tool finalization.

AP is a speaker for Allergan, Ipsen, and Merz and received research support from Allergan, Ipsen, and Revance; SW is a former employee of Ipsen; ED received consultancy fees from Allergan, Ipsen, Merz, and Solstice and research support from Ipsen and Merz.

RESULTS

Patient Interviews

- CE interviews were conducted with 11 patients and caregivers in the US and Canada (3 patients with CD, 4 with spasticity due to stroke, and 4 with spasticity due to cerebral palsy; Table 1) to review the draft questions and discuss the following feedback from within the last year:
- Experience with spasticity
- Perceived changes related to botulinum toxin injections
- Description of experiences and changes from one injection to the next injection

Table 1. Interviews conducted to elicit user feedback

	Condition					
	Cervical dystonia	Cerebral palsy	Spinal cord injury	Stroke	Traumatic brain injury	TOTAL
Muscle Area						
Upper limb	-	1 (torso)	-	2		3
Lower limb	-	4	-	2		6
Neck	3	_	-	_	-	3
CE Interviews (round 1)	3	4*	0	4*	0	11
CE + CD Interviews (round 2)	4-5	3-4	7-8	3-4	7-8	27
TOTAL	7-8	7-8	7-8	7-8	7-8	38
(Included 1 caregiver (parent) of adult chil	٦					

Included 1 caregiver (parent) of adult child CE, concept elicitation; CD, cognitive debriefing.

The Waning of Effect

- For many patients, the waning started around 8 to 10 weeks, even though most were on a 12-week reinjection schedule. Because it takes approximately a week after an injection to achieve the full effect, patients are undertreated for 3-5 weeks of every cycle.
- Patient discussions of waning of indications are summarized in Tables 2 and 3. Across both disease states feelings of being less relaxed and more mentally and physically fatigued were indications of treatment waning, as were symptoms of uncontrolled movement, spasms/ tremors, stiffness, pain, and functional difficulties with walking smoothly.

Table 2. Changes reported at treatment waning in patients with cervical dystonia

Patients with CD, n=3

Patients with CD, n=3				
Feelings	n			
Less control	3			
Less relaxed	2			
More self-conscious; more embarrassed; more fatigue; 1 response each				
Symptoms	n			
Uncontrolled movement	3			
Spasms or tremors	2			
Muscle stiffness/tightening; pain; 1 response each				
Function Difficulties	n			
Driving	3			
Using computer, working at a desk, completing a form	2			
Getting comfortable in bed for sleep (e.g., change sleeping position)	2			
Holding head straight: walking smoothly (with a normal gait); playing golf: 1 response each				

Table 3. Changes reported at treatment waning in patients with spasticity

Patients with spasticity, n=8 Feelings Fatigue Depression Increased strength Risk of injury Independence; embarrassment; self-conscious; control; 1 response each **Symptoms** Muscle stiffness/tightening Uncontrolled movement **Function Difficulties** Put on jacket, pants (buttoning and zippering) Walk fast (have to walk slower) Stand for long periods of time "Harder to do things" Put shoes on Walk smoothly (with a normal gait) Stand up straight Get comfortable in bed for sleep (have to change sleeping position) Getting in/out of bath/shower Toileting (make it to the bathroom; getting up/off toilet) Carry things Coordination Keep good balance Straighten arms Stand from sitting position Straighten out fingers; drive; working at a desk or writing (use hands); bend over; use stairs;

- Data suggest measuring 4 symptoms between injections: uncontrolled large movements, spasm/ tremor, stiffness/tightening, and pain.
- Patient interviews identified several concepts that may be incorporated into future versions: - Driving, working at a computer or desk, and filling out forms will be added as functions.
- Additional details for certain functions that include complex operations may be improved and will be probed during the next phase of cognitive debriefing interviews (eg, getting dressed/undressed may also include putting on shoes, tying shoes, or using buttons).
- Feelings are not explicitly incorporated in the HELP Tool but may be captured by the functional questions.

Advisory Board Discussion

straighten legs; 1 response each

- The current draft of the HELP Tool (Figure 1) was reviewed with consultants during a virtual advisory board meeting. The following was concluded:
- No concepts were missing from the current HELP Tool.
- There is an agreement on the basic need for individualized goal setting and the value of the tool.
- Advisors for CD noted pain as a particularly important symptom.
- CD may need a separate tool from spasticity.
- In pediatric spasticity, goals often change as the child grows.
- Limitations: small initial population; and testing in larger cohorts is still ongoing.

Figure 1. Current draft of the HELP Tool concepts

		Very relevant or Somewhat relevant, r
Hygiene	☐ Brushing hair or teeth	4
	☐ Bathing or showering	4
	☐ Using the toilet (stand from a seated position)	3
	☐ Getting dressed or undressed	5
Activities of Daily Life	□ Eating	4
	☐ Using a computer	4
	□ Drinking	4
	☐ Sleeping	4
	☐ Preparing food or meals	4
	☐ Leisure activities or hobbies	4
	☐ Taking care of others, such as children or elderly parents	4
	☐ Household chores, such as cleaning and doing laundry	3
	☐ Shopping for groceries or other necessary household items	3
	☐ Yardwork/outdoor chores, such as mowing the lawn, gardening	2
	□ Driving	2
Mobility and Physical Function	☐ Sitting upright (with good posture)	6
	☐ Getting in or out of bed	5
	☐ Getting in or out of a chair (or wheelchair)	5
	☐ Getting in or out of a vehicle, such as a car or van	5
	☐ Getting in or out of a bus or train	5
	☐ Standing upright (with good posture)	4
	□ Walking outside	4
	☐ Walking or moving smoothly	4
	☐ Moving around or walking inside	4
	☐ Exercising or participating in other physical activities	4
	☐ Walking or moving quickly	3
	☐ Working outside the home (paid or volunteer)	2
Social Function and Relationships	☐ Sexual activity	4
	☐ Socializing with friends or family	3
	☐ Being in public places (around other people)	3
	☐ Dating or developing intimate relationships	3
	☐ Being physically touched	2

Driving


CONCLUSIONS

- Development and a second round of cognitive debriefing interviews with patients to finalize the HELP Tool are ongoing. Results from the patient CE interviews and advisory board discussions have been presented.
- Based on the first round of patient interviews and the discussion with subject matter experts, the following topics are being considered in the next iteration of the HELP Tool:
- Balance and ambulatory aids (cane, 4-point cane, walker)
- Orthotic use (donning, doffing, comfort for long-term wear)
- -Restriction/tight - Working at a computer or desk; filling out forms
 - Range of motion, posturing
- The HELP Tool data will be used in the development of a user friendly PRO instrument to assist in detecting the waning of treatment effectiveness for use by patients with CD or spasticity and their caregivers.

References Acknowledgments The authors thank all patients involved in the study, as well as consultants and advisory board members. The authors thank Kate Katsaval, BS, and Julie O'Grady, BA, of The Medicine Group LLC, New Hope, PA, USA, for providing medical writing and poster support, which was sponsored by Ipsen,

1. Trompetto C, Marinelli L, Mori L, et al. Biomed Res Int. 2014;2014:354906 2. Jinnah HA, Berardelli A, Comella C, et al. Mov Disord. 2013;28(7):926-943 3. Esquenazi A, Albanese A, Chancellor MB, et al. *Toxicon*. 2013;67:115-128.

4. Simpson DM, Blitzer A, Brashear A, et al. Neurology. 2008;70(19):1699-1706. 5. Jacinto J, Varriale P, Pain E, et al. Front Neurol. 2020;11:388.



Cambridge, MA, USA, in accordance with Good Publication Practice guidelines.